Quantcast
Channel: Endpoints News
Browsing all 3855 articles
Browse latest View live

Trump axes Moderna bird flu pact worth more than $750M

The Trump administration has killed an award worth $766 million to help Moderna develop a bird flu vaccine, according to the company. The biotech said Wednesday that it received notice from the...

View Article


Movement disorder biotech Vima steps onto scene with $60M

Since Bernard Ravina's medical training in neurology in the 1990s, there have been few new therapies that treat a movement disorder known as dystonia. "Nothing fundamentally has changed for these...

View Article


PepGen ditches Duchenne programs after mid-stage fail

PepGen is abandoning its exon 51-skipping Duchenne muscular dystrophy candidate after it failed a Phase 2 trial. And it is getting out of the disease altogether as it discards three preclinical...

View Article

Oric locks down cash for Phase 3 prostate cancer trial with early data in hand

Oric Pharmaceuticals has secured funds to support a planned Phase 3 study of its prostate cancer drug scheduled for 2026 after early results showed “broad and deep” clinical responses. The California...

View Article

FDA rejects Stealth's rare disease drug, but offers potential for accelerated...

After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, the company said early Thursday, but will consider a resubmission via the accelerated...

View Article


Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

Merck and Daiichi Sankyo have pulled the biologics license application for their HER3 antibody-drug conjugate. The companies said Thursday that they voluntarily withdrew the accelerated approval...

View Article

How Illumina’s ex-employees became its customers and competitors

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing company unlocked new frontiers in biology, medicine and business. In doing so,...

View Article

Sanofi’s vaccine tech transfer in Vietnam; Almac’s £1B+ revenue milestone

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Sanofi is partnering with Vietnam Vaccine Company to perform a tech...

View Article


Intellia reports case of liver toxicity in ATTR gene editing study

Intellia Therapeutics disclosed that one patient in a Phase 3 study of its gene editing treatment for a progressive heart disease experienced a serious case of elevated liver enzymes. The patient with...

View Article


Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of...

Plus, news about Immunic, Neurocrine Biosciences, Alcon, AusperBio and Evommune: Taysha Gene Therapies reveals plans for pivotal trial, $200M offering: The biotech on Wednesday disclosed design details...

View Article

Big pharma companies explain why tariffs will harm US investments 

The first wave of biopharma comments on industry-specific tariffs is here. As of Thursday morning, just over 300 of at least 950 public comments have been released by the Department of Commerce in...

View Article

Eisai, Merck stave off generic competition to Lenvima

Eisai and Merck succeeded in stopping Shilpa Medicare Ltd. from launching a generic version of Lenvima for at least another decade, Eisai said Thursday. The Japanese pharma company said it received a...

View Article

The preventive care rebrand

As more healthcare startups pile on the longevity trend, I’ve noticed something familiar about the services they’re touting. Take Midi Health’s new AgeWell program. The virtual care company, best known...

View Article


US urges Supreme Court to decline Oklahoma PBM case

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal government offered its stance on the issue. The US solicitor general this week...

View Article

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a Claudin18.2-targeted antibody-drug conjugate from Evopoint Biosciences. The...

View Article

Browsing all 3855 articles
Browse latest View live